<?xml version="1.0" encoding="UTF-8"?>
<ref id="B101">
 <label>101.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Hung</surname>
    <given-names>IFN</given-names>
   </name>
   <name>
    <surname>Lung</surname>
    <given-names>KC</given-names>
   </name>
   <name>
    <surname>Tso</surname>
    <given-names>EYK</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Chung</surname>
    <given-names>TWH</given-names>
   </name>
   <name>
    <surname>Chu</surname>
    <given-names>MY</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial</article-title>. 
  <source>Lancet.</source> (
  <year>2020</year>) 
  <volume>395</volume>:
  <fpage>1695</fpage>–
  <lpage>704</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31042-4</pub-id>
  <?supplied-pmid 32401715?>
  <pub-id pub-id-type="pmid">32401715</pub-id>
 </mixed-citation>
</ref>
